Cost‐Effectiveness Analysis of Surgical Strategies Versus Medical Management for Rheumatic Heart Disease in Rwanda
Background One‐third of the global rheumatic heart disease burden lies in sub‐Saharan Africa, where 17% of patients with severe rheumatic heart disease die within 3 years without valve surgery. Surgery is often considered uneconomical, although this assumption is not grounded in cost‐effectiveness a...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-06-01
|
| Series: | Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease |
| Subjects: | |
| Online Access: | https://www.ahajournals.org/doi/10.1161/JAHA.124.038365 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849710244096114688 |
|---|---|
| author | Vongai Mlambo Songnan Wang Maurice Musoni Hannah Rando Lambert Ingabire Ceeya Patton‐Bolman Gloria Mukeshimana Evariste Ntaganda Ralph Bolman Eran Bendavid Yihan Lin |
| author_facet | Vongai Mlambo Songnan Wang Maurice Musoni Hannah Rando Lambert Ingabire Ceeya Patton‐Bolman Gloria Mukeshimana Evariste Ntaganda Ralph Bolman Eran Bendavid Yihan Lin |
| author_sort | Vongai Mlambo |
| collection | DOAJ |
| description | Background One‐third of the global rheumatic heart disease burden lies in sub‐Saharan Africa, where 17% of patients with severe rheumatic heart disease die within 3 years without valve surgery. Surgery is often considered uneconomical, although this assumption is not grounded in cost‐effectiveness analyses. Methods We evaluated the cost‐effectiveness of mechanical valve replacement, bioprosthetic valve replacement, and valve repair compared with medical management for patients with severe rheumatic heart disease in Rwanda. Using a Markov model, we simulated disease progression, incorporating transition probabilities from a meta‐analysis of regional observational studies. Costs were calculated using microcosting, and health effects were measured in disability‐adjusted life‐years (DALYs). Cost‐effectiveness was defined by a willingness‐to‐pay threshold of United States dollars (USD) $2307 per DALY, which is 3 times Rwanda's gross domestic product per capita. A 3% discount rate for costs and DALYs was applied. Results Surgical strategies extended life expectancy from 7 to 11 to 13 years. Mechanical and bioprosthetic valve replacements were cost‐effective compared with medical management. Mechanical valve replacement was most efficient, averting 5.64 discounted DALYs for a lifetime discounted cost of USD $10 539.34, with an incremental cost‐effectiveness ratio of USD $1704 per DALY. Bioprosthetic valve replacement averted 5.27 discounted DALYs but incurred higher costs (USD $10 873.06). Valve repair only averted 3.30 DALYs despite being least expensive (USD $8790.19). Repair became the most efficient surgical strategy if valve degeneration rates dropped <3.7% annually. Conclusions Mechanical valve replacement is the most efficient surgical strategy for severe rheumatic heart disease in sub‐Saharan Africa, challenging assumptions that surgery is uneconomical. Reducing surgery costs and optimizing anticoagulation could further enhance cost‐effectiveness. |
| format | Article |
| id | doaj-art-d09606cc7e564e68bb1d6b5c0abb22a6 |
| institution | DOAJ |
| issn | 2047-9980 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease |
| spelling | doaj-art-d09606cc7e564e68bb1d6b5c0abb22a62025-08-20T03:14:58ZengWileyJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease2047-99802025-06-01141110.1161/JAHA.124.038365Cost‐Effectiveness Analysis of Surgical Strategies Versus Medical Management for Rheumatic Heart Disease in RwandaVongai Mlambo0Songnan Wang1Maurice Musoni2Hannah Rando3Lambert Ingabire4Ceeya Patton‐Bolman5Gloria Mukeshimana6Evariste Ntaganda7Ralph Bolman8Eran Bendavid9Yihan Lin10School of Medicine Stanford University Stanford CASchool of Medicine Stanford University Stanford CADepartment of Cardiothoracic Surgery King Faisal Hospital Kigali RwandaDepartment of General Surgery University of Vermont Medical Center Burlington MDKing Faisal Hospital Kigali RwandaTeam Heart Kigali RwandaDepartment of Cardiology King Faisal Hospital Kigali RwandaRwanda Biomedical Center Kigali RwandaDivision of Cardiothoracic Surgery University of Minnesota Minneapolis MNDepartment of Primary Care and Population Health Stanford University Stanford CADepartment of Cardiothoracic Surgery Stanford University Stanford CABackground One‐third of the global rheumatic heart disease burden lies in sub‐Saharan Africa, where 17% of patients with severe rheumatic heart disease die within 3 years without valve surgery. Surgery is often considered uneconomical, although this assumption is not grounded in cost‐effectiveness analyses. Methods We evaluated the cost‐effectiveness of mechanical valve replacement, bioprosthetic valve replacement, and valve repair compared with medical management for patients with severe rheumatic heart disease in Rwanda. Using a Markov model, we simulated disease progression, incorporating transition probabilities from a meta‐analysis of regional observational studies. Costs were calculated using microcosting, and health effects were measured in disability‐adjusted life‐years (DALYs). Cost‐effectiveness was defined by a willingness‐to‐pay threshold of United States dollars (USD) $2307 per DALY, which is 3 times Rwanda's gross domestic product per capita. A 3% discount rate for costs and DALYs was applied. Results Surgical strategies extended life expectancy from 7 to 11 to 13 years. Mechanical and bioprosthetic valve replacements were cost‐effective compared with medical management. Mechanical valve replacement was most efficient, averting 5.64 discounted DALYs for a lifetime discounted cost of USD $10 539.34, with an incremental cost‐effectiveness ratio of USD $1704 per DALY. Bioprosthetic valve replacement averted 5.27 discounted DALYs but incurred higher costs (USD $10 873.06). Valve repair only averted 3.30 DALYs despite being least expensive (USD $8790.19). Repair became the most efficient surgical strategy if valve degeneration rates dropped <3.7% annually. Conclusions Mechanical valve replacement is the most efficient surgical strategy for severe rheumatic heart disease in sub‐Saharan Africa, challenging assumptions that surgery is uneconomical. Reducing surgery costs and optimizing anticoagulation could further enhance cost‐effectiveness.https://www.ahajournals.org/doi/10.1161/JAHA.124.038365cardiac surgerycost‐effectivenessrheumatic heart diseasesub‐Saharan Africa |
| spellingShingle | Vongai Mlambo Songnan Wang Maurice Musoni Hannah Rando Lambert Ingabire Ceeya Patton‐Bolman Gloria Mukeshimana Evariste Ntaganda Ralph Bolman Eran Bendavid Yihan Lin Cost‐Effectiveness Analysis of Surgical Strategies Versus Medical Management for Rheumatic Heart Disease in Rwanda Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease cardiac surgery cost‐effectiveness rheumatic heart disease sub‐Saharan Africa |
| title | Cost‐Effectiveness Analysis of Surgical Strategies Versus Medical Management for Rheumatic Heart Disease in Rwanda |
| title_full | Cost‐Effectiveness Analysis of Surgical Strategies Versus Medical Management for Rheumatic Heart Disease in Rwanda |
| title_fullStr | Cost‐Effectiveness Analysis of Surgical Strategies Versus Medical Management for Rheumatic Heart Disease in Rwanda |
| title_full_unstemmed | Cost‐Effectiveness Analysis of Surgical Strategies Versus Medical Management for Rheumatic Heart Disease in Rwanda |
| title_short | Cost‐Effectiveness Analysis of Surgical Strategies Versus Medical Management for Rheumatic Heart Disease in Rwanda |
| title_sort | cost effectiveness analysis of surgical strategies versus medical management for rheumatic heart disease in rwanda |
| topic | cardiac surgery cost‐effectiveness rheumatic heart disease sub‐Saharan Africa |
| url | https://www.ahajournals.org/doi/10.1161/JAHA.124.038365 |
| work_keys_str_mv | AT vongaimlambo costeffectivenessanalysisofsurgicalstrategiesversusmedicalmanagementforrheumaticheartdiseaseinrwanda AT songnanwang costeffectivenessanalysisofsurgicalstrategiesversusmedicalmanagementforrheumaticheartdiseaseinrwanda AT mauricemusoni costeffectivenessanalysisofsurgicalstrategiesversusmedicalmanagementforrheumaticheartdiseaseinrwanda AT hannahrando costeffectivenessanalysisofsurgicalstrategiesversusmedicalmanagementforrheumaticheartdiseaseinrwanda AT lambertingabire costeffectivenessanalysisofsurgicalstrategiesversusmedicalmanagementforrheumaticheartdiseaseinrwanda AT ceeyapattonbolman costeffectivenessanalysisofsurgicalstrategiesversusmedicalmanagementforrheumaticheartdiseaseinrwanda AT gloriamukeshimana costeffectivenessanalysisofsurgicalstrategiesversusmedicalmanagementforrheumaticheartdiseaseinrwanda AT evaristentaganda costeffectivenessanalysisofsurgicalstrategiesversusmedicalmanagementforrheumaticheartdiseaseinrwanda AT ralphbolman costeffectivenessanalysisofsurgicalstrategiesversusmedicalmanagementforrheumaticheartdiseaseinrwanda AT eranbendavid costeffectivenessanalysisofsurgicalstrategiesversusmedicalmanagementforrheumaticheartdiseaseinrwanda AT yihanlin costeffectivenessanalysisofsurgicalstrategiesversusmedicalmanagementforrheumaticheartdiseaseinrwanda |